To the Editor We are concerned that the study by Dr Vigen and colleagues1 has serious flaws in both design and interpretation.
First, Vigen et al1 characterized testosterone treatment as filling a single prescription for any testosterone product and “once initiated, a patient was assumed to have continued treatment ….” This is insufficient for a definition of long-term testosterone therapy, especially when 17.6% received only 1 prescription. Moreover, there were no data on whether patients continued to regularly receive treatment.
Jones TH, Channer KS. Deaths and Cardiovascular Events in Men Receiving Testosterone. JAMA. 2014;311(9):962-963. doi:10.1001/jama.2014.398